» Articles » PMID: 15039440

The Significance of Circulating Factor IXa in Blood

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2004 Mar 25
PMID 15039440
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

The presence of activation peptides (AP) of the vitamin K-dependent proteins in the phlebotomy blood of human subjects suggests that active serine proteases may circulate in blood as well. The goal of the current study was to evaluate the influence of trace amounts of key coagulation proteases on tissue factor-independent thrombin generation using three models of coagulation. With procoagulants and select coagulation inhibitors at mean physiological concentrations, concentrations of factor IXa, factor Xa, and thrombin were set either equal to those of their AP or to values that would result based upon the rates of AP/enzyme generation and steady state enzyme inhibition. In the latter case, numerical simulation predicts that sufficient thrombin to produce a solid clot would be generated in approximately 2 min. Empirical data from the synthetic plasma suggest clotting times of 3-5 min, which are similar to that observed in contact pathway-inhibited whole blood (4.3 min) initiated with the same concentrations of factors IXa and Xa and thrombin. Numerical simulations performed with the concentrations of two of the enzymes held constant and one varied suggest that the presence of any pair of enzymes is sufficient to yield rapid clot formation. Modeling of states (numerical simulation and whole blood) where only one circulating protease is present at steady state concentration shows significant thrombin generation only for factor IXa. The addition of factor Xa and thrombin has little effect (if any) on thrombin generation induced by factor IXa alone. These data indicate that 1) concentrations of active coagulation enzymes circulating in vivo are significantly lower than can be predicted from the concentrations of their AP, and 2) expected trace amounts of factor IXa can trigger thrombin generation in the absence of tissue factor.

Citing Articles

Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec.

Pittman D, Carrieri C, Soares H, McKay J, Tan C, Liang J Thromb Haemost. 2024; 124(10):912-921.

PMID: 38863155 PMC: 11436294. DOI: 10.1055/s-0044-1787734.


Critical evaluation of kinetic schemes for coagulation.

Ranc A, Bru S, Mendez S, Giansily-Blaizot M, Nicoud F, Rojano R PLoS One. 2023; 18(8):e0290531.

PMID: 37639392 PMC: 10461854. DOI: 10.1371/journal.pone.0290531.


A Review of Quantitative Systems Pharmacology Models of the Coagulation Cascade: Opportunities for Improved Usability.

Chung D, Bakshi S, van der Graaf P Pharmaceutics. 2023; 15(3).

PMID: 36986779 PMC: 10054658. DOI: 10.3390/pharmaceutics15030918.


A System-Wide Investigation and Stratification of the Hemostatic Proteome in Premature Myocardial Infarction.

Dunster J, Wright J, Samani N, Goodall A Front Cardiovasc Med. 2022; 9:919394.

PMID: 35845083 PMC: 9281867. DOI: 10.3389/fcvm.2022.919394.


Factor IX(a) inhibitors: an updated patent review (2003-present).

Afosah D, Ofori E, Mottamal M, Al-Horani R Expert Opin Ther Pat. 2022; 32(4):381-400.

PMID: 34991418 PMC: 8957558. DOI: 10.1080/13543776.2022.2026926.